Incidence of Various Types of Retinal Vein Occlusion and Their Recurrence and Demographic Characteristics

Hayreh, Sohan Singh; Zimmerman, M. Bridget; Podhajsky, Patricia

doi:10.1016/s0002-9394(14)70001-7

Cited by 419 publications

(294 citation statements)

References 21 publications

Supporting

Mentioning

255

Contrasting

Unclassified

Order By: Relevance

“…The commoner risk factors for RVO are similar to those seen in arterial rather than venous thrombosis, notably diabetes, hypertension, and hyperlipidaemia to which can be added local anatomical factors such as open-angle glaucoma. [1][2][3][4][5][6] In RVO studies, the potential pathogenic role(s) of the common causes of thrombophilia, that is, FVL, prothrombin gene mutation, and MTHFR, has given conflicting results. Interestingly, the acquired thrombophilia conditions, hyperhomocysteinaemia, and antiphospholipid syndrome, which cause both arterial and venous thrombosis, are most associated with RVO.…”

Section: Discussionmentioning

confidence: 99%

“…The pathogenesis is multifactorial with open-angle glaucoma, retinal artery disease, and systemic illness; for example, diabetes, hypertension, hyperviscosity, arteriosclerosis, and hyperlipidaemia, all risk factors. [1][2][3][4][5][6] A role for these disorders is in keeping with Virchow's triad of haemostasis and endothelial damage. With the recent identification of common thrombophilic disorders, there has been renewed interest in the third of Virchow's triad, notably hypercoaguability.…”

Section: Introductionmentioning

confidence: 87%

See 1 more Smart Citation

The platelet glycoprotein Ia/IIa gene polymorphism C807T/G873A: a novel risk factor for retinal vein occlusion

Dodson

Haynes

Starczynski

et al. 2003

Eye

View full text Add to dashboard Cite

Retinal vein occlusion (RVO) is associated with hyperhomocysteinaemia and the antiphospholipid syndromeFdisorders known to contribute to both arterial and venous thrombosis. In both of these conditions and RVO, platelet activation occurs. Aspirin, not warfarin, is the most effective antithrombotic agent in RVO and, taken together, these observations suggest an important role for platelets in this common ocular thrombotic condition. Platelet glycoprotein Ia/IIa (GpIa/IIa) is an adhesion molecule mediating platelet-collagen interactions and is key to the initiation of thrombosis. Recently, the cellular density of this molecule was shown to be determined by two silent, linked polymorphisms (C807T/ G873A) within the GpIa/IIa gene. There is evidence that some of the resulting genotypes are associated with thrombo-embolic disease. This study therefore aimed to establish the prevalence of the GpIa/IIa polymorphisms and the three commonest hereditary thrombophilic disorders (prothrombin gene G20210A (PT) mutation, Factor V Leiden (FVL), and the thermolabile methylene tetrahydrofolate reductase C677T (MTHFR) mutation) in patients with RVO and normal controls. The GpIa/IIa polymorphisms and thrombophilic abnormalities were all identified using the polymerase chain reaction. Our results show that the frequency of the GpIa/IIa polymorphisms was similar in our normal control population to previously published series. Patients with RVO, however, had only a 10% (4/40) frequency of the lowest risk subtype (CC/GG) compared to 37.5% (15/40) in the control groupFP 0.0039.The incidence of the PT, FVL, and MTHFR thrombophilic mutations was not different between the two groups, but interestingly none of the 7/40 RVO cases with a PT, FVL, or MTHFR mutation had the low-risk GpIa/IIa genotype while all but one of the controls didFPo0.05. Thus, 17.5% of RVO patients harboured more than one prothrombotic abnormality. The principal difference between the RVO and control group was the very high incidence of the intermediate-risk GpIa/IIa subtype (CT/GA)F82.5 vs 50%, Po0.05. These results suggest a major role for GpIa/IIa polymorphisms in the pathogenesis of RVO.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 87%

The platelet glycoprotein Ia/IIa gene polymorphism C807T/G873A: a novel risk factor for retinal vein occlusion

Dodson

Haynes

Starczynski

et al. 2003

Eye

View full text Add to dashboard Cite

show abstract

“…In my study of 500 consecutive nonischaemic CRVO eyes, it was only 12.6%. 3 Incidence of development of retinal vein occlusion in the fellow eye My findings 3 in 500 consecutive nonischaemic CRVO and 375 consecutive BRVO eyes do not support the information in the Guidelines. The second eye was involved in 7.7% in nonischaemic CRVO and in 6.6% in BRVO.…”

Section: Conversion Of Nonischaemic To Ischaemic Crvomentioning

confidence: 94%

Comment on ‘The Royal College of Ophthalmologists Guidelines on retinal vein occlusions: executive summary’

Hayreh

2016

Eye

View full text Add to dashboard Cite

“…Patients with retinal vein occlusion are more likely to die from a cardiovascular event than those without an occlusion, and the feared complication, unlike retinal artery occlusion, is recurrence of venous occlusion in the fellow eye. The serious risk of recurrent retinal vein occlusion, recorded as 11.9% at 4 years in the fellow eye, 10 underpins the policy of aggressive management of all contributing risk factors. What is not clear is whether an elevated plasma homocysteine level should be lowered in a patient with retinovascular disease.…”

Section: Venous and Arterial Occlusionsmentioning

confidence: 99%

Homocysteine, folates, and the eye

Wright

Martin

Dodson

2007

Eye

View full text Add to dashboard Cite

show abstract

Incidence of Various Types of Retinal Vein Occlusion and Their Recurrence and Demographic Characteristics

Cited by 419 publications

References 21 publications

The platelet glycoprotein Ia/IIa gene polymorphism C807T/G873A: a novel risk factor for retinal vein occlusion

The platelet glycoprotein Ia/IIa gene polymorphism C807T/G873A: a novel risk factor for retinal vein occlusion

Comment on ‘The Royal College of Ophthalmologists Guidelines on retinal vein occlusions: executive summary’

Homocysteine, folates, and the eye

Contact Info

Product

Resources

About